PPI MAX 20: Each enteric-coated tablet contains Esomeprazole magnesium trihydrate equivalent to Esomeprazole 20mg. PPI MAX 40: Each enteric-coated tablet contains Esomeprazole magnesium trihydrate equivalent to Esomeprazole 40mg.
Treatment for duodenal ulcer associated with Helicobacter pylori and Gastro-Esophageal Reflux Disease (GERD).
Gastro-Oesophageal Reflux Disease (GERD) – treatment of erosive reflux oesophagitis 40mg once daily for 4 weeks. An additional 4 weeks treatment is recommended for patients in whom oesophagitis has not healed or who have persistent symptoms. – long-term management of patients with healed oesphagitis to prevent relapse 20mg once daily. – symptomatic treatment of gastro-oesophageal reflux disease (GORD) 20mg once daily in patients without oesophagitis. If symptom control has not been achieved after four weeks, the patient should be further investigated. Once symptoms have resolved, subsequent symptom control can be achieved using 20mg once daily. In adults, an on demand regimen taking 20mg once daily, when needed, can be used. In NSAID treated patients at risk of developing gastric and duodenal ulcers, subsequent symptom control using an on demand regimen is not recommended. Adults: In combination with an appropriate antibacterial therapeutic regimen for the eradication of Helicobacter pylori and, healing of Helicobacter pylori associated duodenal ulcer and prevention of relapse of peptic ulcers in patients with Helicobacter pylori associated ulcers. 20mg of Esomeprazole with 1 g amoxicillin and 500mg clarithromycin, all twice daily for 7 days. Patients requiring continued NSAID theraphy Healing of gastric ulcers associated with NSAID therapy: The usual dose is 20mg once daily. The treatment duration is 4-8 weeks. Prevention of gastric and duodenal ulcers associated with NSAID therapy in patients at risk: 20mg once daily. Treatment of Zollinger Ellison Syndrome The recommended initial dosage is Esomeprazole 40mg twice daily. The dosage should then be individually adjusted and treatment continues as long as clnically indicated. Based on the clinical data available, the majority of patients can be controlled on doses between 80 and 160mg Esomeprazole daily. With doses above 80mg daily, the dose should be divided and given twice-daily.
Hypersensitivity to Esomeprazole, substituted benzimidasoles or any of the excipients. Esomeprazole, like other PPIs, should not be administered with atazanavir.
In the presence of any alarm symptom (e.g. significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis or melaena) and when gastric ulcer is suspected or present, malignancy should be excluded, as treatment with Esomeprazole may alleviate symptoms and delay diagnosis. Patients on long-term treatment (particularly those treated for more than a year).
ASIA PACIFIC – PHILIPPINES
18 Malumanay St.,
Brgy. Sikatuna Village
Diliman Quezon City